CytoDyn Inc announced that its research paper on leronlimab has been accepted by Frontiers in Immunology — a leading journal in its field. publishing rigorously peer-reviewed research across basic, translational and clinical immunology.
The Vancouver, British Columbia-based biotech company said that its study — titled ‘CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody Leronlimab — demonstrated that CCR5+CD4+ T cell levels temporarily increase with leronlimab treatment.
In addition, the study also facilitates future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes.
READ: CytoDyn receives emergency use authorization from Health Canada for leronlimab to treat metastatic triple-negative breast cancer patient
“We are thrilled that the Frontiers in Immunology journal has published this important paper to inform further the scientific community of these exciting developments with leronlimab,” said CytoDyn’s chief medical officer, Scott A. Kelly M.D.
He added: “We will relentlessly pursue the various indications for leronlimab to realize its full therapeutic potential. Our continued work on the mechanism of action of leronlimab continues to lay the foundation for more exciting opportunities of leronlimab for patients and our shareholders.”
CytoDyn, a late-stage biotechnology company, is developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.
CCR5 plays a critical role in the ability of HIV to enter and infect healthy T-cells and appears to be implicated in tumor metastasis and immune-mediated illnesses, such as NASH.
The company successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected patients who were heavily treatment-experienced individuals with limited treatment options.
In July 2021, CytoDyn announced that it had submitted a dose justification report to the FDA, an integral step in the resubmission process for its BLA, which it expects to complete by the end of the first quarter of calendar 2022.
Contact Ritika at ritika@proactiveinvestors.com